01Anchor the reference to an explicit residue interval

The PubChem human angiotensin II record specifies DRVYIHPF with free amino and carboxyl termini. It also identifies the peptide as angiotensin-(1–8).PubChem — Human angiotensin II, CID 172198 (opens in a new tab)

The Roman numeral II is a historical name, not a two-residue count. The interval 1–8 provides a more direct statement of the eight residues included, provided the same angiotensin numbering reference is used.

Do not compare a residue number in angiotensin II with a position in the full precursor without an explicit mapping. A sequence interval is useful precisely because it prevents similar names from obscuring different molecules.

02Formation and removal are separate routes

Rice and colleagues’ 2004 enzyme study described ACE conversion of angiotensin I to angiotensin II and compared peptide cleavage by human ACE, ACE2 and neprilysin. ACE2 efficiently converted angiotensin II to angiotensin-(1–7), whereas neprilysin produced several degradation products.Rice and colleagues — ACE, ACE2 and neprilysin in angiotensin metabolism (opens in a new tab)

The tested ACE inhibitors did not inhibit ACE2. Similar enzyme names therefore did not imply that one inhibitor had the same effect on both proteins.Rice and colleagues — ACE, ACE2 and neprilysin in angiotensin metabolism (opens in a new tab)

For interpretation, a lower angiotensin II measurement could result from reduced formation, increased removal or both. A single concentration does not determine which route changed. Measuring the relevant products and enzyme activities helps distinguish those possibilities.

03Keep the endogenous ligand separate from biased analogues

Wingler and colleagues’ 2020 structural study compared the AT1 receptor bound to angiotensin II and to two modified ligands with strong beta-arrestin bias. The structures represented different active receptor conformations associated with those ligand profiles.Wingler and colleagues — Angiotensin and biased analogue receptor conformations (opens in a new tab)

The comparison uses the endogenous peptide as a reference. It does not make the analogues unchanged angiotensin II, or establish that activation of the receptor has one identical downstream consequence for every ligand.

A label such as active receptor is therefore only a starting point. Read which output was measured and which ligand was used. Comparing pathways requires matched experimental context rather than borrowing a receptor-level adjective from another assay.

This reference does not rank biased ligands as clinically better or safer. Such a ranking requires direct outcome evidence and cannot be obtained from a receptor conformation alone.

04Place each angiotensin experiment at the correct step

For an enzyme experiment, identify substrate, enzyme and products. For a receptor experiment, identify ligand, receptor construct and functional readout. For an organism-level experiment, identify the intervention and the physiological outcome.

These records can be connected into a mechanism, but they should not be counted as interchangeable demonstrations of one effect. Preventing ligand formation and blocking a receptor alter different parts of the system.

A useful explanation might say that an enzyme produced a shorter peptide or that a specified analogue favoured a particular measured pathway. Each statement is more informative than saying that the angiotensin system was improved.

Keeping the steps explicit allows readers to follow the research without turning the pathway into personal blood-pressure advice. This is a molecular reference, not guidance on administering peptides or altering prescribed medicines.